EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly three months after it recommended approval for the drug to treat some patients with early Alzheimer's disease.
Biogen, Eisai Alzheimer’s drug review delayed in EU
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's drug regulator to reconsider a prior decision that endorsed the anti-amyloid therapy.
FDA clears monthly dosing of Alzheimer’s drug Leqembi
The approval is the first to come from the FDA since the Trump administration paused external communication by health agencies last week.
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi. Post the FDA approval, patients have the option to transition to a monthly maintenance dosing regimen of Leqembi after completing an 18-month course of biweekly infusions of the drug.
FIU News13d
Promising new drug candidate for Alzheimer’s
Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...
Verywell Health on MSN3d
Why It's Hard for Patients to Get the Newest Alzheimer's Drugs
Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...
Medscape2d
Alzheimer’s Disease: The Cholinergic Revival
A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...
Alzheimer’s Association names top 5 advances in care for 2024
New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...
Verywell Health on MSN6d
What's New in Alzheimer's Treatment?
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Surprising New Research Links Common Medications to Reduced Dementia Risk
New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...
Medical News Today9d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
‘Repurposing’ current drugs to tackle dementia an ‘urgent priority’ – experts
“Viral and bacterial infectious causes of common dementias have been proposed, supported by epidemiological data linking ...
Hosted on MSN3d
Common cholesterol drug offers new hope for millions of Alzheimer's patients
Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...